Supplementary Materials:

Supplementary Figure 1: Study Design and Inclusion/Exclusion Criteria

Adherence (PDC ≥ 0.8) Indicators month wise during the one year after index prescription date

6 Months baseline

| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |

Jan 1, 2010

Index Prescription Date:
(Oral fingolimod vs Injectable)

Dec 31, 2012

Patient selection period range (September 20, 2010 – December 31, 2011)

Inclusion Criteria:
(i)   Age ≥18 Years,
(ii)   MS diagnosed patients with Index DMA Prescription, and
(iii)   Continuous Eligibility during baseline 6 and follow-up 12 months
**Exclusion Criteria:**
(i)   Combination medication users, and
(ii)   Teriflunomide users

PDC=Proportion of days covered

Supplementary Figure 2: Adherence Trajectories with 4 and 5 groups, and for oral and injectable DMA users separately

a) Four Groups

Adherence Trajectories
4 groups, 2 order

b) Five Groups

Adherence Trajectories
5 groups, 2 order

C. Trajectories for Oral and Injectable DMA Users Separately

Oral DMA users
**Adherence Trajectories**
3 groups, 2 order

Injectable DMA users
Adherence Trajectories
3 groups, 2 order

Supplementary Figure 3: Standardized Differences between Covariates of Oral Fingolimod and Injectable DMA Users Before and After IPTW Matching

Standardized differences before and after IPTW
Threshold: -0.25 to 0.25

Abbreviations: MS – Multiple Sclerosis, DMA – Disease Modifying Agent, IPTW - inverse probability treatment weights